Haemonetics
Provider of blood and plasma supplies and services.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $600m | Post IPO Convertible |
| Total Funding | 000k | ||
| USD | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 14 % | 18 % | 12 % | 4 % | (4 %) | 7 % | 10 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 17 % | 21 % | 21 % | 23 % | 33 % | 33 % | 32 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 4 % | 10 % | 9 % | 12 % | 15 % | 16 % | 17 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 5 % | 4 % | 4 % | 5 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Haemonetics Corporation is a leading provider of innovative medical technology solutions aimed at improving the quality, effectiveness, and efficiency of healthcare. The company primarily serves healthcare professionals and institutions, including hospitals and plasma donation centers. Haemonetics operates in the medical technology market, focusing on critical care settings where patient outcomes and economic efficiency are paramount.
The company's business model revolves around developing and selling advanced medical products and services. These include technologies that enhance plasma yield collections, boost productivity, and improve the donor experience in plasma centers. By offering these solutions, Haemonetics helps healthcare providers optimize their operations, leading to better patient care and improved economic outcomes.
Haemonetics generates revenue through the sale of its medical technology products and services. This includes both one-time sales of equipment and recurring revenue from service contracts and consumables used in their devices. The company is also committed to corporate responsibility, actively managing environmental, social, and governance risks and opportunities.
In summary, Haemonetics is dedicated to advancing patient care through innovative medical technologies, serving healthcare professionals and institutions in critical care settings, and maintaining a strong focus on corporate responsibility.
Keywords: medical technology, healthcare, plasma collection, patient care, productivity, donor experience, economic outcomes, innovation, corporate responsibility, critical care.
Tech stack
Investments by Haemonetics
Edit
